Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

6,000 heart patients to be studied for better valve care

NCT ID NCT07230756

Knowledge-focused Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 6,000 people in China who have both coronary heart disease and a leaky heart valve (ischemic mitral regurgitation). Researchers will collect medical data and track outcomes like hospitalizations and deaths over two years. The goal is to understand the disease better and find ways to improve diagnosis and treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide doctors with better tools to predict and manage heart valve problems in people with coronary heart disease.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or procedure, so it cannot directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with coronary heart disease combined with ischemic mitral regurgitation

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, secondary mitral regurgitation discovered during outpatient visit or hospitalization; * Have definite coronary heart disease * Cardiac ultrasound: consistent with mitral regurgitation caused by myocardial ischemia or myocardial infarction: 1. Segmental wall motion abnormality or 2. Mitral regurgitation is consistent with Carpentier type IIIb (eccentric regurgitation) * Cardiac ultrasound prompts: moderate or above ischemic mitral regurgitation Exclusion Criteria: * Patients within the past year or currently participating in other clinical studies; * Primary mitral regurgitation (such as mitral valve prolapse, perforation, chordae tendineae rupture, etc.); * Dilated cardiomyopathy, hypertrophic cardiomyopathy and other diseases; * Moderate and above aortic stenosis/regurgitation, mitral stenosis, tricuspid stenosis, etc.; * Patients who have undergone cardiac valve intervention/surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease (CHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary heart disease (CHD) Ischemic mitral regurgitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.